Updates on Allergies and Immunodeficiencies

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Hematology and Immunology".

Deadline for manuscript submissions: 30 April 2026 | Viewed by 305

Special Issue Editors


E-Mail Website
Guest Editor
1. Center of Immuno-Physiology and Biotechnologies, Department of Functional Sciences, “Victor Babeș” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
2. Timis County Emergency Clinical Hospital “Pius Brinzeu”, 156 Liviu Rebreanu Bd., 300723 Timisoara, Romania
Interests: molecular allergology; asthma; food allergy; recombinant allergens; allergen immunotherapy; immunology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor Assistant
Center of Immuno‐Physiology and Biotechnologies, Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
Interests: molecular allergology; allergenic proteins; recombinant allergens; allergen immunotherapy

Special Issue Information

Dear Colleagues,

Allergic diseases and immunodeficiencies are becoming a major health issue, affecting patients’ quality of life and placing a substantial burden on healthcare systems worldwide. The pathogenesis of these conditions is driven by multiple factors including genetic predisposition, environmental factors, and intricate immune system dynamics. Over the last decades, advances in molecular diagnostics, component-resolved allergy testing, and targeted therapies have improved the understanding and management of allergic diseases. However, important gaps remain in identifying new allergens and allergen sources, understanding the immune mechanisms, developing reliable biomarkers, and translating research findings into clinical practice. Additionally, immunodeficiencies, whether primary or acquired, are often underdiagnosed or recognized late, leading to severe complications. Early detection and effective management are critical for improving patient outcomes and reducing healthcare burdens.

This Special Issue aims to present a comprehensive overview of recent advancements in the fields of allergy and immunodeficiency. Therefore we invite researchers to contribute with original research articles and review papers that advance knowledge and promote progress within the diagnosis and management of these disorders.

Potential topics include, but are not limited to, the following:

  • Molecular and cellular mechanisms of allergic and immunodeficiency disorders;
  • Identification and structural characterization of novel allergens;
  • Clinical significance of allergen cross-reactivity;
  • Development of precision immunotherapies and novel treatment strategies;
  • Influence of environmental agents on immune response.

We look forward to receiving your contributions.

Dr. Carmen Panaitescu
Guest Editor

Dr. Maria Roxana Buzan
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • allergy
  • immunodeficiency
  • allergens
  • cross-reactivity
  • molecular allergy diagnostics
  • immunotherapy
  • precision medicine
  • exposome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

10 pages, 429 KB  
Brief Report
Hereditary Angioedema Prophylaxis Therapy: Berotralstat and Lanadelumab Safety Profile
by Mattia Donadoni, Leyla La Cava, Emanuele Bizzi, Valentina Popescu Janu, Alessia Meschia, Federica Cirigliano, Chiara Cogliati and Antonio Gidaro
Medicina 2025, 61(11), 1897; https://doi.org/10.3390/medicina61111897 - 23 Oct 2025
Viewed by 218
Abstract
Background and Objectives: Hereditary angioedema caused by C1 inhibitor deficiency (HAE-C1-INH) is a rare genetic condition characterized by recurrent, potentially life-threatening episodes of angioedema. Long-term prophylaxis (LTP) is essential for decreasing the frequency and severity of attacks. This study aims to compare [...] Read more.
Background and Objectives: Hereditary angioedema caused by C1 inhibitor deficiency (HAE-C1-INH) is a rare genetic condition characterized by recurrent, potentially life-threatening episodes of angioedema. Long-term prophylaxis (LTP) is essential for decreasing the frequency and severity of attacks. This study aims to compare the safety profiles of two first-line LTP therapies, both of which inhibit kallikrein: berotralstat (oral) and lanadelumab (subcutaneous), using data from the WHO’s VigiBase pharmacovigilance database. Materials and Methods: The study employed a retrospective quantitative design, utilizing the World Health Organization’s pharmacovigilance database, VigiAccess, which contains individual case safety reports of adverse drug reactions (ADRs) to identify cases of ADRs associated with HAE-C1-INH long-term prophylaxis. Results: A total of 644 reports for berotralstat and 3432 reports for lanadelumab were analyzed. Berotralstat was mainly associated with gastrointestinal adverse events (47.9%), while lanadelumab was linked to injection site reactions (45.9%), infections (23.3%), musculoskeletal and connective tissue disorders (10%), immune system disorders (5.3%), vascular disorders (4.7%), and metabolic issues (3.9%). Female patients were more frequently affected in both groups. Statistically significant differences were observed, reflecting the differences in administration methods and pharmacological profiles between the two drugs. Limitations include the self-reported nature of the data and the absence of detailed clinical information. Conclusions: The results confirmed the literature’s data on the gastrointestinal adverse effects of berotralstat, as well as site reactions and infections associated with lanadelumab. Notably, musculoskeletal and connective tissue disorders, immune system disorders, vascular disorders, and metabolic issues occurred more frequently in patients using lanadelumab. Full article
(This article belongs to the Special Issue Updates on Allergies and Immunodeficiencies)
Show Figures

Figure 1

Back to TopTop